Rituximab therapy for Severe and Persistent Lichenoid drug-reaction
Abstract
We report on a patient with severe and fixed lichenoid drug-reaction. She did not respond to 2 months treatment with high-dose corticosteroids. Hence, Rituximab was given. One month later, her lesions improved and remained stable for 14 months of follow up.
Keywords: fixed drug reaction, Prednesone, Rituximab.
Downloads
Download data is not yet available.
References
1- Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129:1088.
2- Sehgal VN, Srivastava G, Sharma S, Sehgal S, Verma P. Lichenoid tissue reaction/interface dermatitis: Recognition, classification, etiology, and clinicopathological overtones. Indian Journal of Dermatology, Venereology and Leprology 2011; 77:418-430.
3- Ellgehausen P, Elsner P, Berger G. Drug induced lichen planus. Clin Dermatol 1998; 16:325-332.
4- Sehgal VN, Srivastava G. Fixed Drug Eruption (FDE): Changing scenario of incriminating drugs. Int J Dermatol 2006; 45:897-908.
5- Bayer HealthCare Pharmaceuticals Inc. Cipro (ciprofloxacin hydrochloride) tablets and Cipro (ciprofloxacin) for oral suspension prescribing information. Whippany, NJ; 2016 Jul.
6- Shai A, Halevy S. Lichen Planus and lichen planus-like eruptions: Pathogenesis and associated diseases. Int J Dermatol 1992; 31:379-84.
7- Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminitive criteria between lichenoid drug eruption and idiopathic lichen planus: Retrospective study on selected samples. Dermatoloica 1989; 179:10-13.
8- Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev2005; 4:236-241.
9- Mizukawa Y, Shiohara T. Fixed drug eruption: A prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9:71-77.
10- Crowson AN, Magro CM, Mihm MC Jr. Interface Dermatitis. Arch Pathol Lab Med 2008; 132:652-666.
11- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
12- Johnson P, Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30:(sup.2):2-8.
13- Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is a B cell dependent. J Immunol 2001; 167:4710-4718.
14- Muhammad K, Roll P, Einsele H, Dorner T, Tony HP. Delayed acquisition of somatic hypermutations in repopulated IgD+CD27+memory B cell receptors after rituximab treatment. Arthritis Rheum 2009; 60:2284-2293
2- Sehgal VN, Srivastava G, Sharma S, Sehgal S, Verma P. Lichenoid tissue reaction/interface dermatitis: Recognition, classification, etiology, and clinicopathological overtones. Indian Journal of Dermatology, Venereology and Leprology 2011; 77:418-430.
3- Ellgehausen P, Elsner P, Berger G. Drug induced lichen planus. Clin Dermatol 1998; 16:325-332.
4- Sehgal VN, Srivastava G. Fixed Drug Eruption (FDE): Changing scenario of incriminating drugs. Int J Dermatol 2006; 45:897-908.
5- Bayer HealthCare Pharmaceuticals Inc. Cipro (ciprofloxacin hydrochloride) tablets and Cipro (ciprofloxacin) for oral suspension prescribing information. Whippany, NJ; 2016 Jul.
6- Shai A, Halevy S. Lichen Planus and lichen planus-like eruptions: Pathogenesis and associated diseases. Int J Dermatol 1992; 31:379-84.
7- Van den Haute V, Antoine JL, Lachapelle JM. Histopathological discriminitive criteria between lichenoid drug eruption and idiopathic lichen planus: Retrospective study on selected samples. Dermatoloica 1989; 179:10-13.
8- Shiohara T, Mizukawa Y. The immunological basis of lichenoid tissue reaction. Autoimmun Rev2005; 4:236-241.
9- Mizukawa Y, Shiohara T. Fixed drug eruption: A prototypic disorder mediated by effector memory T cells. Curr Allergy Asthma Rep 2009; 9:71-77.
10- Crowson AN, Magro CM, Mihm MC Jr. Interface Dermatitis. Arch Pathol Lab Med 2008; 132:652-666.
11- Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005; 31:456-473.
12- Johnson P, Glennie M. The mechanism of action of rituximab in the elimination of tumor cells. Semin Oncol 2003; 30:(sup.2):2-8.
13- Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell activation in rheumatoid synovium is a B cell dependent. J Immunol 2001; 167:4710-4718.
14- Muhammad K, Roll P, Einsele H, Dorner T, Tony HP. Delayed acquisition of somatic hypermutations in repopulated IgD+CD27+memory B cell receptors after rituximab treatment. Arthritis Rheum 2009; 60:2284-2293
Crossmark
Statistics
380 Views | 291 Downloads
How to Cite
1.
El-Reshaid K, Al-Bader S. Rituximab therapy for Severe and Persistent Lichenoid drug-reaction. JDDT [Internet]. 15Jun.2019 [cited 30Apr.2024];9(3-s):751-3. Available from: https://www.jddtonline.info/index.php/jddt/article/view/2873
Section
Case Studies
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.